Matthew A. Powell

5.8k total citations · 1 hit paper
170 papers, 3.9k citations indexed

About

Matthew A. Powell is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Matthew A. Powell has authored 170 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Obstetrics and Gynecology, 65 papers in Reproductive Medicine and 48 papers in Oncology. Recurrent topics in Matthew A. Powell's work include Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (63 papers) and Cervical Cancer and HPV Research (27 papers). Matthew A. Powell is often cited by papers focused on Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (63 papers) and Cervical Cancer and HPV Research (27 papers). Matthew A. Powell collaborates with scholars based in United States, Canada and Netherlands. Matthew A. Powell's co-authors include David G. Mutch, Janet S. Rader, Randall K. Gibb, Jason D. Wright, Perry W. Grigsby, Thomas J. Herzog, Barry A. Siegel, Farrokh Dehdashti, Premal H. Thaker and Perry W. Grigsby and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Matthew A. Powell

156 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

2024 58 citations Giorgio Bogani, Bradley J. Monk et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Matthew A. Powell

Since Specialization

Citations

This map shows the geographic impact of Matthew A. Powell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Powell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Powell more than expected).

Fields of papers citing papers by Matthew A. Powell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Powell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Powell. The network helps show where Matthew A. Powell may publish in the future.

Co-authorship network of co-authors of Matthew A. Powell

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Powell. A scholar is included among the top collaborators of Matthew A. Powell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Powell. Matthew A. Powell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study	International Journal of Gynecological Cancer	Ignace Vergote, David Cibula et al.	1
2	Clinical Images: Vasculitic rash as a presenting symptom of heparin‐induced thrombocytopenia in a woman with primary antiphospholipid syndrome	ACR Open Rheumatology	Kevin Thompson, Matthew A. Powell et al.	0
3	Prophylactic antibiotics for excision of premalignant vulvar lesions: A pilot randomized controlled trial	Gynecologic Oncology Reports	Whitney R. Grither, David G. Mutch et al.	0
4	Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer breakdown →	Annals of Oncology	Giorgio Bogani, Bradley J. Monk et al.	58
5	Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial	Journal of Clinical Oncology	Ann H. Klopp, Danielle Enserro et al.	10
6	Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study	Cancer	Ian S. Hagemann, Sarah M. Temkin et al.	1
7	Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial	Gynecologic Oncology	Sharad Ghamande, Lars Hanker et al.	11
8	740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial	Annals of Oncology	Mansoor Raza Mirza, Sudarshan Sharma et al.	20
9	750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial	Annals of Oncology	Brian M. Slomovitz, Robert L. Coleman et al.	2
10	Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)	Gynecologic Oncology	Mansoor Raza Mirza, Dana M. Chase et al.	2
11	NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer	Cancer	B.J. Rimel, Danielle Enserro et al.	6
12	A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)	Obstetrical & Gynecological Survey	János L. Tanyi, Leslie M. Randall et al.	0
13	PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)		Roisin E. O’Cearbhaill, Michael W. Sill et al.	0
14	Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.	JCO Oncology Practice	Mansoor Raza Mirza, Mark S. Shahin et al.	1
15	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial	Journal of Clinical Oncology	Matthew A. Powell, Virginia L. Filiaci et al.	47
16	GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis	Molecular Cancer Therapeutics	Kevin Cho, Elena Lomonosova et al.	10
17	Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use	Gynecologic Oncology	Sarah P. Huepenbecker, Lindsay M. Kuroki et al.	7
18	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer	Molecular Cancer Therapeutics	Ian S. Hagemann, Lei Guo et al.	24
19	The Utility and Management of Vaginal Cytology After Treatment for Endometrial Cancer	Obstetrics and Gynecology	Akiva P. Novetsky, Lindsay M. Kuroki et al.	11
20	Efficacy and biocompatibility of a photopolymerized, synthetic, absorbable hydrogel as a dural sealant in a canine craniotomy model	Journal of neurosurgery	Cargill H. Alleyne, Daniel L. Barrow et al.	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact